Market Overview

BioLineRx to Report Interim Results of Phase II/III Trial for Schizophrenia Drug BL-1020 During Week of March 18, 2013

BioLineRx (NASDAQ: BLRX) announced today that the results of the interim analysis of the
Phase II/III CLARITY trial of BL-1020, a first in class, orally
available, GABA-enhanced antipsychotic for the treatment of
schizophrenia, are expected during the week beginning March 18, 2013.
The interim analysis will be performed on data of approximately 235
randomized patients from 27 sites in Romania and India. The primary
endpoint of the analysis will be the six-week effect of the drug on
cognitive function, which is a principal deficit in schizophrenia
patients.

The interim analysis will be performed by a fully independent, external
Data Monitoring Committee (DMC), which will maintain complete blinding

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (BLRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters